HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation - Phase 1 Study Results
Overview
Request a copy of our scientific poster titled, 'HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation - Phase 1 Study Results.'
HBI-3000 (sulcardine sulfate trihydrate; Bai, et al. 2012) is a multi-ion channel blocker with effects on INa-Peak, INa-Late, ICa,L, and IKr with similar in vitro potencies across these various ion channels in human atrial cardiomyocytes. It is being eveloped by HUYA Bioscience International® (HUYABIO™) for the conversion of recent onset atrial fibrillation (AF).